|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
|
CA2070823C
(en)
|
1989-12-05 |
1999-01-12 |
William H. Ii Frey |
Neurologic agents for nasal administration to the brain
|
|
US6407061B1
(en)
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
|
CA2099503C
(en)
|
1991-11-14 |
2007-10-09 |
Hamish Steele Scott |
Synthetic alpha-l-iduronidase and genetic sequences encoding same
|
|
FR2716893B1
(fr)
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
|
US6190659B1
(en)
|
1996-09-17 |
2001-02-20 |
The Rockefeller University |
Bacterial plasmin binding protein and methods of use thereof
|
|
AU8672198A
(en)
|
1997-07-31 |
1999-02-22 |
Chiron Corporation |
Method enabling readministration of aav vector via immunosuppression of host
|
|
WO1999061066A2
(en)
|
1998-05-27 |
1999-12-02 |
Avigen, Inc. |
Convection-enhanced delivery of aav vectors
|
|
US7273618B2
(en)
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
ES2252993T3
(es)
|
1998-12-09 |
2006-05-16 |
Chiron Corporation |
Administracion de agentes neurotroficos al sistema nervioso central.
|
|
EP1135105B1
(en)
|
1998-12-09 |
2005-03-02 |
Chiron Corporation |
Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
|
|
CA2379166C
(en)
|
1999-08-09 |
2013-03-26 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
|
|
US6426208B1
(en)
|
1999-11-12 |
2002-07-30 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
US6569661B1
(en)
|
1999-11-12 |
2003-05-27 |
Biomarin Pharmaceutical Inc. |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
US6585971B1
(en)
|
1999-11-12 |
2003-07-01 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
|
|
US6582692B1
(en)
|
1999-11-17 |
2003-06-24 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
|
WO2001041782A2
(en)
|
1999-12-09 |
2001-06-14 |
Chiron Corporation |
Method for administering a cytokine to the central nervous system and the lymphatic system
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
CA2412882A1
(en)
|
2000-06-30 |
2002-01-10 |
Maxygen Aps |
Peptide extended glycosylated polypeptides
|
|
EP2767291B1
(en)
|
2000-07-18 |
2016-09-14 |
Duke University |
Treatment of glycogen storage disease type II
|
|
US20020014242A1
(en)
|
2000-07-31 |
2002-02-07 |
Abraham Scaria |
Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
|
|
US20020082215A1
(en)
|
2000-10-13 |
2002-06-27 |
Chiron Corporation |
Method for treating ischemic events affecting the central nervous system
|
|
US20020169102A1
(en)
|
2001-04-03 |
2002-11-14 |
Frey William H. |
Intranasal delivery of agents for regulating development of implanted cells in the CNS
|
|
WO2002086105A1
(en)
|
2001-04-20 |
2002-10-31 |
Chiron Corporation |
Delivery of polynucleotide agents to the central nervous sysstem
|
|
MX359371B
(es)
|
2001-11-13 |
2018-09-25 |
Univ Pennsylvania |
Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
|
|
PT1453547T
(pt)
|
2001-12-17 |
2016-12-28 |
Univ Pennsylvania |
Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
|
|
US20070004743A1
(en)
|
2002-02-25 |
2007-01-04 |
Xiao Linda L |
Intranasal administration of mc4-r agonists
|
|
US7485314B2
(en)
|
2002-05-06 |
2009-02-03 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Induction of antigen specific immunologic tolerance
|
|
AU2003302724A1
(en)
|
2002-08-13 |
2004-07-09 |
Mcivor, Scott, R. |
Methods of using vectors to treat metabolic disorders
|
|
CA2499170A1
(en)
|
2002-09-27 |
2004-04-08 |
Children's Medical Center Corporation |
Methods and compositions for treatment of neurological disorder
|
|
US8512710B2
(en)
|
2002-11-22 |
2013-08-20 |
Ansun Biopharma, Inc. |
Class of therapeutic protein based molecules
|
|
US7446098B2
(en)
|
2003-02-18 |
2008-11-04 |
Mount Sinai School Of Medicine Of New York University |
Combination therapy for treating protein deficiencies
|
|
CA2500523A1
(en)
|
2003-05-01 |
2004-11-18 |
University Of Florida Research Foundation, Inc. |
Vp2-modified raav vector compositions and uses therefor
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
EP2345731B1
(en)
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
US8071364B2
(en)
|
2003-12-24 |
2011-12-06 |
Transgenrx, Inc. |
Gene therapy using transposon-based vectors
|
|
US7776312B2
(en)
|
2004-08-13 |
2010-08-17 |
Healthpartners Research Foundation |
Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
|
|
US7618615B2
(en)
|
2004-08-13 |
2009-11-17 |
Healthpartners Research Foundation |
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
|
|
US20090136505A1
(en)
|
2005-02-23 |
2009-05-28 |
Johanna Bentz |
Intranasal Administration of Active Agents to the Central Nervous System
|
|
US20060188496A1
(en)
|
2005-02-23 |
2006-08-24 |
Hanne Bentz |
Intranasal administration of active agents to the central nervous system
|
|
ES2525067T3
(es)
|
2005-04-07 |
2014-12-17 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
|
JP4495210B2
(ja)
|
2005-06-09 |
2010-06-30 |
パナソニック株式会社 |
振幅誤差補償装置及び直交度誤差補償装置
|
|
JP5276982B2
(ja)
|
2005-08-26 |
2013-08-28 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
オキシトシンの投与による頭痛の処置のための方法
|
|
AR059371A1
(es)
|
2006-02-08 |
2008-03-26 |
Genzyme Corp |
Terapia genica para la enfermedad de niemann-pick tipo a
|
|
HUE040490T2
(hu)
|
2006-02-09 |
2019-03-28 |
Genzyme Corp |
Lassú intraventrikuláris szállítás
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
US8153604B2
(en)
|
2006-04-24 |
2012-04-10 |
Geron Corporation |
CNS-tumor treatment method and composition
|
|
EP1915986A1
(en)
|
2006-10-23 |
2008-04-30 |
BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH |
Lipid growth factor formulations
|
|
EP2132309A4
(en)
|
2007-02-23 |
2011-01-05 |
Univ Florida |
COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
ES2635726T3
(es)
|
2007-06-06 |
2017-10-04 |
Genzyme Corporation |
Terapia génica para enfermedades de almacenamiento lisosómico
|
|
EP2152240A4
(en)
|
2007-06-08 |
2012-05-09 |
Healthpartners Res Foundation |
PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
|
|
US8283160B2
(en)
|
2007-09-11 |
2012-10-09 |
Frey Ii William H |
Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
ES2751999T3
(es)
|
2008-01-29 |
2020-04-02 |
Applied Genetic Tech Corporation |
Producción recombinante de virus adeno-asociados usando células BHK en suspensión
|
|
US9265843B2
(en)
|
2008-03-27 |
2016-02-23 |
The Ohio State University |
Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
|
|
WO2009137006A2
(en)
|
2008-04-30 |
2009-11-12 |
The University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
|
WO2010071832A1
(en)
|
2008-12-19 |
2010-06-24 |
Nationwide Children's Hospital |
Delivery of polynucleotides across the blood brain barrier using recombinant aav9
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
US7989502B2
(en)
|
2009-02-06 |
2011-08-02 |
Sri International |
Intranasal delivery of modafinil
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
US20110070241A1
(en)
|
2009-06-30 |
2011-03-24 |
Duke University |
Methods for modulating immune responses to aav gene therapy vectors
|
|
US8622993B2
(en)
|
2009-12-18 |
2014-01-07 |
Healthpartners Research Foundation |
Device and method for delivering therapeutic substances to the maxillary sinus of a patient
|
|
SG183512A1
(en)
|
2010-03-03 |
2012-09-27 |
Teva Pharma |
Treatment of lupus nephritis using laquinimod
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
EP2394667A1
(en)
|
2010-06-10 |
2011-12-14 |
Laboratorios Del Dr. Esteve, S.A. |
Vectors and sequences for the treatment of diseases
|
|
HRP20191923T1
(hr)
|
2010-06-25 |
2020-01-10 |
Shire Human Genetic Therapies, Inc. |
Postupci i sastavi za isporuku arilsulfataze a u cns
|
|
LT2588130T
(lt)
|
2010-06-25 |
2016-12-12 |
Shire Human Genetic Therapies, Inc. |
Terapinės priemonės pristatymas cns
|
|
JP6073783B2
(ja)
|
2010-06-25 |
2017-02-01 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
|
|
PT3103469T
(pt)
|
2010-06-25 |
2021-03-04 |
Shire Human Genetic Therapies |
Administração de agentes terapêuticos no snc
|
|
KR20230159646A
(ko)
|
2010-06-25 |
2023-11-21 |
샤이어 휴먼 지네틱 테라피즈 인크. |
이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
|
|
WO2012101671A1
(en)
|
2011-01-25 |
2012-08-02 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human recombinant iduronate 2-sulfatase
|
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
TR201908020T4
(tr)
|
2011-02-17 |
2019-06-21 |
Univ Pennsylvania |
Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
|
|
WO2012135857A1
(en)
|
2011-03-31 |
2012-10-04 |
University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
|
WO2012145597A2
(en)
|
2011-04-21 |
2012-10-26 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
|
EP2709670A4
(en)
|
2011-05-18 |
2015-01-21 |
Childrens Hosp Medical Center |
TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
US9387236B2
(en)
|
2011-06-10 |
2016-07-12 |
Prothera Inc. |
Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
|
|
EP2736539B1
(en)
|
2011-07-25 |
2017-08-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
SG10201510106PA
(en)
|
2011-10-12 |
2016-01-28 |
Synageva Biopharma Corp |
Recombinant human naglu protein and uses thereof
|
|
US9821149B2
(en)
|
2011-10-14 |
2017-11-21 |
Healthpartners Research & Education |
Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
|
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
AU2012346448B2
(en)
|
2011-12-02 |
2017-09-14 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
JP6188728B2
(ja)
|
2012-02-07 |
2017-08-30 |
グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
核酸送達の区画化方法ならびにその組成物および使用
|
|
EP2829236B1
(en)
|
2012-03-23 |
2019-06-26 |
Terumo Kabushiki Kaisha |
Puncture instrument and puncture device
|
|
KR20150020250A
(ko)
|
2012-06-19 |
2015-02-25 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
당뇨병을 치료하기 위한 조성물 및 방법
|
|
US20150182637A1
(en)
|
2012-06-21 |
2015-07-02 |
Association Institut De Myologie |
Widespread gene delivery of gene therapy vectors
|
|
AU2013296425B2
(en)
|
2012-08-01 |
2018-06-07 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
US12024568B2
(en)
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
ES2729997T3
(es)
|
2012-11-27 |
2019-11-07 |
Biomarin Pharm Inc |
Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
|
|
WO2014125647A1
(ja)
|
2013-02-18 |
2014-08-21 |
富士通オプティカルコンポーネンツ株式会社 |
光受信装置
|
|
AU2014235096B2
(en)
|
2013-03-15 |
2020-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating MPSI
|
|
MX388221B
(es)
|
2013-04-20 |
2025-03-19 |
Res Institute At Nationwide Children´S Hospital |
ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
|
|
MX380973B
(es)
|
2013-05-01 |
2025-03-12 |
Genzyme Corp |
Composiciones y metodos para tratar la atrofia muscular espinal.
|
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
EP3024497B1
(en)
|
2013-07-26 |
2021-01-13 |
University of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
HK1225258B
(en)
|
2013-08-08 |
2017-09-08 |
Global Bio Therapeutics, Inc. |
Clamping device for minimally invasive surgery
|
|
SI3702466T1
(sl)
|
2013-08-27 |
2023-04-28 |
Research Institute At Nationwide Children's Hospital |
Proizvodi in postopki za zdravljenje amiotrofične lateralne skleroze
|
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
|
CN105745326A
(zh)
|
2013-10-24 |
2016-07-06 |
优尼科Ip有限公司 |
用于基因治疗神经疾病的aav-5假型载体
|
|
EP3134113A4
(en)
|
2014-04-25 |
2017-11-29 |
University of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
|
US10053671B2
(en)
|
2014-06-20 |
2018-08-21 |
Wisconsin Alumni Research Foundation (Warf) |
Mutations that confer genetic stability to additional genes in influenza viruses
|
|
AU2015320694B2
(en)
|
2014-09-24 |
2021-11-11 |
City Of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
HK1256341A1
(zh)
|
2015-05-15 |
2019-09-20 |
明尼苏达大学董事会 |
用於治疗性递送到中枢神经系统的腺相关物
|
|
EP3101125A1
(en)
|
2015-06-05 |
2016-12-07 |
Laboratorios Del Dr. Esteve, S.A. |
Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CN108779167A
(zh)
|
2015-10-28 |
2018-11-09 |
宾夕法尼亚州大学信托人 |
鞘内施用腺伴随病毒载体用于基因治疗
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
CA3012195A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
EP3411484B1
(en)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
US10561894B2
(en)
|
2016-03-18 |
2020-02-18 |
Icon Health & Fitness, Inc. |
Treadmill with removable supports
|
|
SG10201912761UA
(en)
*
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
JP2020500928A
(ja)
|
2016-11-15 |
2020-01-16 |
リジェネクスバイオ インコーポレイテッド |
Ｍｐｓｉおよびｍｐｓｉｉならびに他の神経障害において神経機能を改善するための方法
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
IL316926A
(en)
|
2017-05-11 |
2025-01-01 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinosis
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
KR102883778B1
(ko)
|
2017-09-22 |
2025-11-12 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
|
IL280198B2
(en)
|
2018-07-18 |
2026-01-01 |
Regenxbio Inc |
Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
|
|
US20240084917A1
(en)
|
2019-10-07 |
2024-03-14 |
Wartsila Services Switzerland Ltd. |
Step lift control of hydraulically actuated popped valves
|
|
KR20220131522A
(ko)
|
2020-01-22 |
2022-09-28 |
리젠엑스바이오 인크. |
완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
|